Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.
Rafael Holdings Inc Class B (NYSE:RFL) shares fell 25% in pre-market trading on Wednesday after the company’s Phase 3 TransportNPC trial of Trappsol Cyclo in patients with Niemann-Pick Disease Type C (NPC) failed to meet its primary endpoint. The study enrolled 94 patients and evaluated the change from baseline in the 4-domain NPC Clinical Severity Scale at Week 96.
Trappsol® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing approximately 83% of the study population, showed a statistically significant effect on the 4DNPCSS Trappsol® Cyclo™ demonstrated a well-tolerated safety and tolera
This is the newest page. Registered accounts read further back.